Skip to main content

Bradley Lorimier, James Niedel

Premium

Psychiatric Genomics of Gaithersburg, Md., which uses gene expression analysis of brain and other human tissues to develop medications for mental illness, has appointed Bradley Lorimier to its board of directors and as a business development consultant. Lorimer currently consults within the pharmaceutical industry and serves on the boards of four companies. Lorimer retired from his position as senior vice president of business development for Human Genome Sciences in 1997. Before joining HGS, Lorimer also served in management positions at Johnson & Johnson, Sterling Drug, and Revlon Health Care Group.

Sprout Group, a venture capital affiliate of Credit Suisse First Boston, has hired former GlaxoSmithKline chief science and technology officer James Niedel as a partner for health-care technology investments. Between 1995 and 2001, Niedel oversaw global R&D, information technology, and product strategy at GlaxoWellcome.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.